<DOC>
	<DOCNO>NCT01420042</DOCNO>
	<brief_summary>The purpose study obtain evidence safety determine pharmacokinetics ( PK ) NNZ-2566 healthy volunteer , administer orally .</brief_summary>
	<brief_title>Safety Study NNZ-2566 Healthy Subjects , Following Oral Administration</brief_title>
	<detailed_description>Double-blind , placebo-controlled , randomize ( 6:2 randomization active versus placebo ) safety , dose-escalation , pharmacokinetic study NNZ-2566 . Three cohort sequentially dose , start two cohort receive single dose ( 6mg/kg follow 30mg/kg ) . The third cohort receive two 100mg/kg dos course one day follow formal safety review subject receive two 100mg/kg dos day five day .</detailed_description>
	<mesh_term>Brain Injuries</mesh_term>
	<criteria>Males : 60.0100.0 kg , Females : 50.0100.0 kg ( inclusive ) . Males : Body mass index ( BMI ) 2030.0 , Females : BMI 18.530.0 kg/m2 ( inclusive ) . Healthy , determine medical history particular attention : drug history identify know drug allergy presence drug abuse ; chronic use medication thorough review body system : clinically significant abnormal finding physical examination electrocardiogram ( ECG ) , Adequate venous access arm allow collection blood sample . Fluent English language . Have voluntarily give write informed consent . Pregnant lactating female . History allergy/hypersensitivity ingredient formulation History clinically significant gastrointestinal , hepatic , renal , cardiovascular , dermatological , immunological , respiratory , endocrine , oncological , neurological , metabolic , gynecological , ENT musculoskeletal disorder , psychiatric disease hematological disorder . Any history asthma last 10 year . Creatinine clearance &lt; 65 mL/min . Any predisposing condition might interfere absorption , distribution , metabolism , and/or excretion investigational product . History abnormal bleeding tendency thrombophlebitis unrelated venepuncture . History hepatitis B , positive test hepatitis B surface antigen , history hepatitis C , positive test hepatitis C antibody , history HIV infection demonstration HIV antibody . Any evidence organ dysfunction , clinically significant clinical laboratory value , opinion Investigator would jeopardize safety subject impact validity study result , include liver function test ( LFT ) &gt; 1.5 x upper limit normal ( ULN ) . Those may difficulty abstain alcohol 48 hr prior dose administration completion Study Exit visit . History , current evidence , abuse alcohol drug substance , licit illicit , positive urine drug screen drug abuse . Difficulty abstain prescription medication 14 day prior dose administration duration study . Difficulty abstain overthecounter ( OTC ) medication herbal supplement 14 day prior dose administration duration study , ( exception occasional analgesia , vitamin nutrient supplement use , discretion Investigator ) . Difficulty abstain food and/or beverage contain caffeine xanthine , ( e.g . coffee , tea , cola chocolate ) 48 hrs prior dose administration duration study . History psychiatric illness may impair ability provide write informed consent . Poor compliers unlikely attend . Receipt drug part research study within 30 day initial dose administration study . Standard blood donation ( usually 550 mL ) within 12week period dose administration . Unusual dietary habit excessive unusual vitamin intake . Vaccination immunization within 30 day initial dose administration . Whilst QT/QTc effect see human volunteer dose 20 mg/kg administer intravenously 10 min infusion , effect drug QT/QTc interval formally characterize , study use exclusion criterion define International Conference Harmonisation ( ICH ) Guideline E14 exclude subject risk QT/QTc prolongation , namely : A marked baseline prolongation correct QT interval &gt; 450 m two ECGs , A history risk factor Torsade de Pointes ( e.g. , heart failure , hypokalemia , family history Long QT Syndrome ) .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>50 Years</maximum_age>
	<verification_date>November 2012</verification_date>
</DOC>